Tg(TetO-MYC*)4Gev
Transgene Detail
|
|
| Symbol: |
Tg(TetO-MYC*)4Gev |
| Name: |
transgene insertion 4, Gerard Evan |
| MGI ID: |
MGI:4366289 |
| Synonyms: |
Tg(TRE-omoMYC)4Gev, TRE-Omomyc |
| Transgene: |
Tg(TetO-MYC*)4Gev Location: unknown
|
| Alliance: |
Tg(TetO-MYC*)4Gev page
|
|
|
|
| Transgene Type: |
|
Transgenic (Dominant negative, Humanized sequence, Inducible, Inserted expressed sequence) |
| Inducer: |
|
doxycycline/tetracycline |
| Mutation: |
|
Insertion
|
| |
|
Mutation details: This transgene permits conditional inhibition of MYC via expression, driven by the cytomegalovirus (CMV) early promoter and regulated by the tetracycline responsive element (TRE or TetO), of a dominant interfering mutant MYC bHLHZip dimerization domain. The expressed protein is a human MYC-derived basic helix-loop-helix zipper (bHLHZip) domain in which replacement of four charged amino acids (Glu57Thr, Glu64Ile, Arg70Glu, Arg71Asn) permits it to form homodimers, as well as heterodimers with endogenous MYC that interfere with the formation of MYC/MAX dimers and suppress binding to E-box elements. In doubly transgenic mice also expressing the tetracycline transactivating or reverse transactivating element (tTA or rtTA), expression of the MYC inhibitor can be regulated by doxycycline administration or removal.
(J:141029, J:153799)
|
|
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
|
| Original: |
J:141029 Soucek L, et al., Modelling Myc inhibition as a cancer therapy. Nature. 2008 Oct 2;455(7213):679-83 |
| All: |
8 reference(s) |
|
Analysis Tools
